Skip to main content
On August 27, 2013, global education company Pearson plc announced it had acquired BioBehavioral Diagnostics (BioBDx) and its flagship Quotient System, a computerized attention deficit hyperactivity disorder (ADHD) assessment and management system approved by the U.S. Food and Drug Administration (FDA) in 2002 to aid in diagnosing ADHD. Financial terms of the transaction were not disclosed. For Pearson, the acquisition provides an entry into health care markets, and a way of meeting its goal of providing for educational needs across a spectrum of individuals. Pearson plans to focus on increasing awareness and use of the Quotient . . .
Content Restricted

This article is reserved for members with an active Standard Membership. Please purchase a Standard Membership to view this resource.

Purchase A Standard Account

Tagged As:

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!

Close

Support Request

Need help now?

Call our toll-free phone number 877-350-6463